Md. Aynal Haque

Mohammad Zunaed, Md. Aynal Haque, Taufiq Hasan

Performance degradation due to distribution discrepancy is a longstanding challenge in intelligent imaging, particularly for chest X-rays (CXRs). Recent studies have demonstrated that CNNs are biased toward styles (e.g., uninformative textures) rather than content (e.g., shape), in stark contrast to the human vision system. Radiologists tend to learn visual cues from CXRs and thus perform well across multiple domains. Motivated by this, we employ the novel on-the-fly style randomization modules at both image (SRM-IL) and feature (SRM-FL) levels to create rich style perturbed features while keeping the content intact for robust cross-domain performance. Previous methods simulate unseen domains by constructing new styles via interpolation or swapping styles from existing data, limiting them to available source domains during training. However, SRM-IL samples the style statistics from the possible value range of a CXR image instead of the training data to achieve more diversified augmentations. Moreover, we utilize pixel-wise learnable parameters in the SRM-FL compared to pre-defined channel-wise mean and standard deviations as style embeddings for capturing more representative style features. Additionally, we leverage consistency regularizations on global semantic features and predictive distributions from with and without style-perturbed versions of the same CXR to tweak the model's sensitivity toward content markers for accurate predictions. Our proposed method, trained on CheXpert and MIMIC-CXR datasets, achieves 77.32$\pm$0.35, 88.38$\pm$0.19, 82.63$\pm$0.13 AUCs(%) on the unseen domain test datasets, i.e., BRAX, VinDr-CXR, and NIH chest X-ray14, respectively, compared to 75.56$\pm$0.80, 87.57$\pm$0.46, 82.07$\pm$0.19 from state-of-the-art models on five-fold cross-validation with statistically significant results in thoracic disease classification.

Partho Ghosh, Md. Aynal Haque

The discovery of novel drug target (DT) interactions is an important step in the drug development process. The majority of computer techniques for predicting DT interactions have focused on binary classification, with the goal of determining whether or not a DT pair interacts. Protein ligand interactions, on the other hand, assume a continuous range of binding strength values, also known as binding affinity, and forecasting this value remains a difficulty. As the amount of affinity data in DT knowledge-bases grows, advanced learning techniques such as deep learning architectures can be used to predict binding affinities. In this paper, we present a deep-learning-based methodology for predicting DT binding affinities using just sequencing information from both targets and drugs. The results show that the proposed deep learning-based model that uses the 1D representations of targets and drugs is an effective approach for drug target binding affinity prediction and it does not require additional chemical domain knowledge to work with. The model in which high-level representations of a drug and a target are constructed via CNNs that uses residual skip connections and also with an additional stream to create a high-level combined representation of the drug-target pair achieved the best Concordance Index (CI) performance in one of the largest benchmark datasets, outperforming the recent state-of-the-art method AttentionDTA and many other machine-learning and deep-learning based baseline methods for DT binding affinity prediction that uses the 1D representations of targets and drugs.